Commensal Lactobacillus Controls Immune Tolerance during Acute Liver Injury in Mice
Nobuhiro Nakamoto,
Takeru Amiya,
Ryo Aoki,
Nobuhito Taniki,
Yuzo Koda,
Kentaro Miyamoto,
Toshiaki Teratani,
Takahiro Suzuki,
Sayako Chiba,
Po-Sung Chu,
Atsushi Hayashi,
Akihiro Yamaguchi,
Shunsuke Shiba,
Rei Miyake,
Tadashi Katayama,
Wataru Suda,
Yohei Mikami,
Nobuhiko Kamada,
Hirotoshi Ebinuma,
Hidetsugu Saito,
Masahira Hattori,
Takanori Kanai
Affiliations
Nobuhiro Nakamoto
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 1608582, Japan; Corresponding author
Takeru Amiya
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 1608582, Japan; Research Unit/Frontier Therapeutic Sciences, Sohyaku, Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Kanagawa 2270033, Japan
Ryo Aoki
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 1608582, Japan; Institute of Health Science, Ezaki Glico Co., Ltd., Osaka 5558502, Japan
Nobuhito Taniki
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 1608582, Japan
Yuzo Koda
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 1608582, Japan; Research Unit/Frontier Therapeutic Sciences, Sohyaku, Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Kanagawa 2270033, Japan
Kentaro Miyamoto
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 1608582, Japan; Miyarisan Pharmaceutical Co., Ltd., Research Laboratory, Tokyo 1140016, Japan
Toshiaki Teratani
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 1608582, Japan
Takahiro Suzuki
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 1608582, Japan
Sayako Chiba
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 1608582, Japan
Po-Sung Chu
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 1608582, Japan
Atsushi Hayashi
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 1608582, Japan; Miyarisan Pharmaceutical Co., Ltd., Research Laboratory, Tokyo 1140016, Japan
Akihiro Yamaguchi
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 1608582, Japan
Shunsuke Shiba
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 1608582, Japan
Rei Miyake
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 1608582, Japan
Tadashi Katayama
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 1608582, Japan
Wataru Suda
Department of Microbiology, Keio University School of Medicine, Tokyo 1608582, Japan; Laboratory of Metagenomics, Graduate School of Frontier Sciences, The University of Tokyo, Chiba 2778561, Japan
Yohei Mikami
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 1608582, Japan
Nobuhiko Kamada
Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
Hirotoshi Ebinuma
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 1608582, Japan
Hidetsugu Saito
Division of Pharmacotherapeutics, Keio University School of Pharmacy, Tokyo 1058512, Japan
Masahira Hattori
Laboratory of Metagenomics, Graduate School of Frontier Sciences, The University of Tokyo, Chiba 2778561, Japan; Cooperative Major in Advanced Health Science, Graduate School of Advanced Science and Engineering, Faculty of Science and Engineering, Waseda University, Tokyo 1698555, Japan
Takanori Kanai
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 1608582, Japan; Corresponding author
Summary: Gut-derived microbial antigens trigger the innate immune system during acute liver injury. During recovery, regulatory immunity plays a role in suppressing inflammation; however, the precise mechanism underlying this process remains obscure. Here, we find that recruitment of immune-regulatory classical dendritic cells (cDCs) is crucial for liver tolerance in concanavalin A-induced acute liver injury. Acute liver injury resulted in enrichment of commensal Lactobacillus in the gut. Notably, Lactobacillus activated IL-22 production by gut innate lymphoid cells and raised systemic IL-22 levels. Gut-derived IL-22 enhanced mucosal barrier function and promoted the recruitment of regulatory cDCs to the liver. These cDCs produced IL-10 and TGF-β through TLR9 activation, preventing further liver inflammation. Collectively, our results indicate that beneficial gut microbes influence tolerogenic immune responses in the liver. Therefore, modulation of the gut microbiota might be a potential option to regulate liver tolerance. : Nakamoto et.al. find that Lactobacillus accumulates in the gut and activates IL-22 production by innate lymphoid cells during acute liver injury. Gut-derived IL-22 contributes to liver tolerance via induction of regulatory DCs. Keywords: immune tolerance, dendritic cell, innate lymphoid cell, acute liver injury, interleukin-10, interleukin-22, microbiota, dysbiosis